Tirzepatide vs VK2735: Dual Agonist Showdown for Obesity Treatment

Introduction#

Tirzepatide and VK2735 are both dual GLP-1/GIP receptor agonists, making this a direct class-level comparison between an approved market leader and an emerging challenger. Tirzepatide (Mounjaro/Zepbound) by Eli Lilly was the first dual incretin agonist to reach market, demonstrating the largest body weight reductions of any approved anti-obesity pharmacotherapy and proving that dual GLP-1/GIP agonism produces superior outcomes to GLP-1 agonism alone.

VK2735 by Viking Therapeutics is following the same dual agonist approach but with a distinct molecular structure and -- critically -- both injectable and oral formulations in development. The VENTURE phase 2 trials showed rapid weight loss that, while measured over only 13 weeks, generated enthusiasm about VK2735's potential to compete with established agents.

This comparison evaluates the current evidence for both drugs while acknowledging the fundamental asymmetry: tirzepatide has extensive phase 3 data and FDA approval, while VK2735 has promising but limited phase 2 results.

Mechanism of Action Comparison#

Tirzepatide#

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor. Its potency profile is imbalanced: approximately 5-fold greater potency at GIPR relative to native GIP and about 0.2-fold the potency of native GLP-1 at GLP-1R.

This dual agonism produces synergistic metabolic effects beyond what either pathway achieves alone. GIP receptor activation potentiates insulin secretion, may improve lipid metabolism and fat distribution, and enhances central appetite regulation through mechanisms complementary to GLP-1R signaling. A C20 fatty diacid modification enables albumin binding and a half-life of approximately 5 days.

VK2735#

VK2735 is also a dual GLP-1 and GIP receptor agonist, but with a distinct molecular design from tirzepatide. While the specific structural details and receptor potency ratios have not been fully disclosed, VK2735 activates both incretin pathways and is designed for once-weekly subcutaneous injection as well as daily oral administration.

The development of an oral formulation is a key differentiator from tirzepatide and most other dual agonists in development.

Mechanistic Comparison#

Dosing Comparison#

Tirzepatide Dosing#

Tirzepatide uses a unified escalation schedule for both indications:

• Starting dose: 2.5 mg weekly for 4 weeks
• Escalation: 2.5 mg increments at minimum 4-week intervals
• Dose range: 2.5, 5, 7.5, 10, 12.5, 15 mg
• First therapeutic dose: 5 mg
• Maximum: 15 mg weekly

Supplied as single-dose pre-filled pens with hidden needle design. Six pen strengths available.

VK2735 Dosing#

VK2735 dosing remains investigational:

• Subcutaneous (VENTURE): Multiple dose cohorts with weekly injections over 13 weeks
• Oral (VENTURE-Oral): Daily dosing up to 90 mg over 13 weeks
• Maintenance: Exploratory data supports down-titration from 90 mg to 30 mg orally for weight maintenance

Phase 3 dose selection has not been publicly announced.

Side Effects Comparison#

Tirzepatide Side Effects#

Tirzepatide's GI side effect profile is well characterized through the SURPASS and SURMOUNT programs. Nausea occurs in 12-33%, diarrhea in 12-21%, and vomiting in 5-13%. In the head-to-head SURPASS-2 trial, tirzepatide demonstrated comparable or slightly better GI tolerability than semaglutide 1 mg despite producing greater metabolic effects. Fewer than 1% of tirzepatide patients discontinued due to nausea in SURPASS trials.

Tirzepatide carries the same boxed warning as other incretin therapies for thyroid C-cell tumors based on rodent data.

VK2735 Side Effects#

VK2735 safety data is limited to short-term phase 2 trials. In the VENTURE-Oral trial, vomiting was reported in 26% of VK2735-treated subjects vs 10% placebo. However, 99% of GI-specific adverse events were mild or moderate. The most common reasons for discontinuation were GI-related.

Long-term safety, rare adverse events, and effects on the cardiovascular system have not been characterized.

Safety Comparison Table#

Research Evidence Comparison#

Tirzepatide Research#

Tirzepatide has extensive phase 3 evidence:

• SURPASS (T2D): Five trials, >9,000 patients. SURPASS-2 showed superiority over semaglutide 1 mg for HbA1c (-2.46% vs -1.86%) and weight (-12.4 kg vs -6.2 kg) at 40 weeks
• SURMOUNT (obesity): SURMOUNT-1 demonstrated 20.9% mean weight loss at 72 weeks (15 mg). 36% of patients achieved 25% or more reduction
• SURPASS-CVOT: Cardiovascular outcomes trial underway

Evidence level: High -- large RCTs, head-to-head data, FDA-approved.

VK2735 Research#

VK2735's evidence is limited to phase 2:

• VENTURE (subcutaneous): 176 adults, 13 weeks, up to 14.7% weight loss from baseline (13.1% placebo-adjusted)
• VENTURE-Oral: Oral tablet, 13 weeks, up to 12.2% weight loss vs 1.3% placebo
• VANQUISH (phase 3): Planned

Evidence level: Low -- phase 2 only, short duration, no head-to-head comparisons.

Key Differences Summary#

• Same class, different stage: Both are dual GLP-1/GIP agonists, but tirzepatide is FDA-approved while VK2735 is in early clinical development.
• Efficacy data: Tirzepatide has demonstrated 20.9% weight loss at 72 weeks. VK2735 showed 14.7% at 13 weeks with weight still declining, making direct comparison difficult.
• Oral formulation: VK2735's most significant differentiator. Tirzepatide is injectable only. VK2735's oral tablet showed 12.2% weight loss at 13 weeks in phase 2.
• Diabetes evidence: Tirzepatide has robust T2D data with HbA1c reductions up to 2.58% and head-to-head superiority over semaglutide. VK2735 has not been studied in diabetes.
• Head-to-head data: Tirzepatide proved superiority over semaglutide in SURPASS-2. VK2735 has no head-to-head comparisons.
• Cardiovascular outcomes: Neither has completed a CVOT, though tirzepatide's SURPASS-CVOT is underway.

Conclusion#

Tirzepatide is the established leader in the dual GLP-1/GIP agonist class, with the largest weight reductions of any approved anti-obesity medication, proven glycemic superiority over semaglutide, and a growing body of real-world evidence. For patients seeking treatment today, tirzepatide is the clear recommendation.

VK2735 is the most interesting emerging competitor within the same dual agonist class, primarily because of its oral formulation. If phase 3 trials confirm the efficacy suggested by VENTURE data and demonstrate an acceptable long-term safety profile, an oral GLP-1/GIP dual agonist could address the significant unmet need for patients who prefer pills to injections. However, VK2735 must still complete pivotal trials, obtain regulatory approval, and demonstrate that its oral bioavailability translates into competitive long-term efficacy.

The competitive landscape is important context: VK2735 will enter a market that already includes tirzepatide (dual agonist, injectable), semaglutide (GLP-1, injectable and oral), and orforglipron (oral GLP-1, if approved). VK2735's path to commercial success will depend on demonstrating clear differentiation in this crowded field.

Further Reading#

• Tirzepatide Overview and Research Guide
• Tirzepatide Side Effects
• Tirzepatide Dosing Protocols
• VK2735 Overview and Research Guide
• VK2735 Side Effects
• VK2735 Dosing Protocols